DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
Gerassimos J. Mantzaris(European CanCer Organisation), Brian Bressler(University of British Columbia), Emma Billmyer(Analysis Group (United States)), Andrés Yarur(Cedars-Sinai Medical Center), Michelle Luo(University of North Carolina at Chapel Hill), Shashi Adsul(Takeda (United States)), Shu Wang(Xi'an Jiaotong University), Ha Nam Nguyen(Auburn University), A. Guérin(Analysis Group (United States)), Pravin Kamble(Takeda (United States))
Cited by 7
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478